Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study-Reference-Cited by-同舟云学术

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: A multicentre Hellenic Cooperative Oncology Group phase II study

Published:2008-01 Issue:6 Volume:47 Page:1148-1155
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Pentheroudakis George,Briasoulis Evangelos,Kalofonos Haralambos P.,Fountzilas Georgios,Economopoulos Theofanis,Samelis George,Koutras Aris,Karina Maria,Xiros Nikolaos,Samantas Epameinondas,Bamias Aristotelis,Pavlidis Nikolaos

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/02841860701843043

Reference32 articles.

1. Cancer of unknown primary (CUP)

2. Diagnostic and therapeutic management of cancer of an unknown primary

3. Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?

4. Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary;Molecular Therapy;2024-07

2. Case Report: Combined pembrolizumab, 5-fluorouracil, and cisplatin therapy were remarkably effective in p16-positive squamous cell carcinoma of unknown primary;Frontiers in Oncology;2023-07-10

3. Synergic activity of FGFR2 and MEK inhibitors in the treatment of FGFR2-amplified cancers of unknown primary;2023-03-17

4. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary;Molecular Oncology;2021-06-23

5. Using Advanced Molecular Profiling to Identify the Origin of and Tailor Treatment for an Intracranial Mass of Unknown Primary;JCO Precision Oncology;2021-05